Tags

Type your tag names separated by a space and hit enter

Use of newly available febuxostat in a case of chronic tophaceous gout contraindicated to allopurinol and probenecid.
Med J Malaysia. 2012 Feb; 67(1):125-6.MJ

Abstract

Urate lowering therapy in this country has mainly been achieved by the use of allopurinol and probenecid. A new xanthine oxidase inhibitor called febuxostat has been approved in 2009 for treatment of hyperuricaemia in gout. In this report, we describe the management of a patient with chronic tophaceous gout using febuxostat. The reduction in serum uric acid to target levels was rapid, and the tophi size had also reduced significantly while on therapy. There was no unwanted side effect observed during the therapy. Therefore, febuxostat would be a useful alternative drug in the treatment of hyperuricaemia in gout patients who have contraindications to allopurinol and probenecid.

Authors+Show Affiliations

International Islamic University Malaysia, Internal Medicine, Jalan Hospital, Kuantan, Pahang 25100 Malaysia. drh_1@hotmail.comNo affiliation info availableNo affiliation info available

Pub Type(s)

Case Reports
Journal Article

Language

eng

PubMed ID

22582566

Citation

Hilmi, B A., et al. "Use of Newly Available Febuxostat in a Case of Chronic Tophaceous Gout Contraindicated to Allopurinol and Probenecid." The Medical Journal of Malaysia, vol. 67, no. 1, 2012, pp. 125-6.
Hilmi BA, Asmahan MI, Rosman A. Use of newly available febuxostat in a case of chronic tophaceous gout contraindicated to allopurinol and probenecid. Med J Malaysia. 2012;67(1):125-6.
Hilmi, B. A., Asmahan, M. I., & Rosman, A. (2012). Use of newly available febuxostat in a case of chronic tophaceous gout contraindicated to allopurinol and probenecid. The Medical Journal of Malaysia, 67(1), 125-6.
Hilmi BA, Asmahan MI, Rosman A. Use of Newly Available Febuxostat in a Case of Chronic Tophaceous Gout Contraindicated to Allopurinol and Probenecid. Med J Malaysia. 2012;67(1):125-6. PubMed PMID: 22582566.
* Article titles in AMA citation format should be in sentence-case
TY - JOUR T1 - Use of newly available febuxostat in a case of chronic tophaceous gout contraindicated to allopurinol and probenecid. AU - Hilmi,B A, AU - Asmahan,M I, AU - Rosman,A, PY - 2012/5/16/entrez PY - 2012/5/16/pubmed PY - 2012/6/6/medline SP - 125 EP - 6 JF - The Medical journal of Malaysia JO - Med J Malaysia VL - 67 IS - 1 N2 - Urate lowering therapy in this country has mainly been achieved by the use of allopurinol and probenecid. A new xanthine oxidase inhibitor called febuxostat has been approved in 2009 for treatment of hyperuricaemia in gout. In this report, we describe the management of a patient with chronic tophaceous gout using febuxostat. The reduction in serum uric acid to target levels was rapid, and the tophi size had also reduced significantly while on therapy. There was no unwanted side effect observed during the therapy. Therefore, febuxostat would be a useful alternative drug in the treatment of hyperuricaemia in gout patients who have contraindications to allopurinol and probenecid. SN - 0300-5283 UR - https://www.unboundmedicine.com/medline/citation/22582566/Use_of_newly_available_febuxostat_in_a_case_of_chronic_tophaceous_gout_contraindicated_to_allopurinol_and_probenecid_ L2 - http://www.e-mjm.org/2012/v67n1/Febuxostat.pdf DB - PRIME DP - Unbound Medicine ER -